Zimmer and Anika expand Orthovisc deal:
This article was originally published in Clinica
Zimmer and Anika Therapeutics have extended their exclusive, multi-year distribution agreement for Orthovisc, an injectable product based on hyaluronic acid to restore the elasticity and viscosity of the synovial fluid. Under the new agreement, Zimmer will sell the product in Europe and Latin America. Anika will receive up to $3.5 million. The two companies' initial agreement covered the US, Canada and certain Asia-Pacific countries.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.